Kidney cancer: progress and controversies in neoadjuvant therapy

Area of Science:

• Oncology
• Nephrology
• Surgical Oncology

Background:

• Neoadjuvant therapy is increasingly explored in renal cell carcinoma (RCC).
• Kinase inhibitors are clinically active agents used in cancer treatment.
• Pre-surgical (neoadjuvant) treatment aims to reduce tumor burden and facilitate surgery.

Purpose of the Study:

• To evaluate the safety and feasibility of neoadjuvant kinase inhibitors in patients undergoing nephrectomy.
• To assess the impact of neoadjuvant therapy on primary tumor size.
• To determine the overall clinical benefit of neoadjuvant axitinib.

Main Methods:

• Administration of clinically active agents, including kinase inhibitors.
• Surgical nephrectomy following neoadjuvant treatment.
• Assessment of tumor size reduction and surgical approach optimization.

Main Results:

• Neoadjuvant use of clinically active agents, such as kinase inhibitors, was found to be safe and feasible.
• This approach demonstrated a decrease in primary tumor size, aiding surgical optimization.
• The overall clinical benefit of neoadjuvant axitinib has not yet been established.

Conclusions:

• Neoadjuvant therapy with kinase inhibitors is a safe and feasible option before nephrectomy.
• Tumor size reduction is achievable, potentially improving surgical outcomes.
• Further research is needed to confirm the overall clinical benefit of neoadjuvant toxic drugs like axitinib.